



Therapix to develop a cannabinoid-based drug for treating impairments in cognitive functioning and preventing Alzheimer's disease based on research conducted at Tel Aviv University

Entered into an MOU with the University's tech-transfer company, whereby it shall fund a research project for developing and adapting a technology related to low dosages of THC for treating cognitive functioning impairments.

June 28, 2015

Therapix Biosciences announces that it has entered into a non-binding memorandum of understandings with Ramot, Tel Aviv University's technology transfer company, whereby the Company shall fund a research project at the Tel Aviv University for developing and adapting a technology related to ultralow dosages of THC (the active substance in cannabis) for treating mild cognitive impairments, including ailments such as early stages of Alzheimer's disease. In consideration for the project's funding, the Company will receive a license from Ramot for the technology emerging from the research project.

The research program is expected to be conducted over a 12-month period, and it shall be funded by Therapix in consideration for an exclusive, worldwide license from Ramot, bearing various payments defined in the agreement. The parties are negotiating a definitive agreement and have signed a "No-Shop" agreement for a term of four months, until the parties shall have reached a final and binding agreement. In exchange for the agreement, the Company shall pay Ramot royalties out of the total sales as well as milestone-based payments which include sales targets and regulatory approval targets.

The research project of Tel Aviv University (Ramot) is based on the works and experiments of a team led by Prof. Yosef Sarne. In studies published in prestigious journals (*Experimental Brain Research* and *Journal of Neuroscience Research*) it was found that certain cannabinoid active substances (THC) facilitate the recovery of memory and other cognitive abilities, at low and ultralow dosages.

Prof. Sarne discovered that a low dosage of cannabis slows down brain-cell destruction and may prevent diseases such as Alzheimer's and even the natural age-dependent deterioration of the brain.

Dr. Asher Shmulewitz, the Company's Chairman, stated that "Ramot's project is groundbreaking and shall join Therapix's additional technologies in an envisaged collaborative development of a medical product that may prevent degenerative ailments of the brain such as Alzheimer's disease. Prof. Sarne's research was filed as a patent and was validated by additional laboratories around the world. Therapix intends to begin a clinical study upon conclusion of the research".